Anzeige
❌
Mehr »
Mittwoch, 18.11.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Quantensicherheit! Ist diese Aktie noch völlig unterschätzt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DoFDA appears to pause controversial speedy review program, complete response letter disclosures
DoOrzeyful's 'lighter' DEA schedule paves way for Takeda's first-in-class narcolepsy launch
DoRadiopharma player PharmaLogic snaps up Lantheus' CDMO business, plant as Curium acquisition advances
DoAI models from Google, Anthropic and more lean on recommending promoted drugs: study
11.11.FDA cites record request breakdowns in trio of warning letters to API makers
11.11.Legend Biotech shares fall 16% after first earnings report under new CEO
11.11.BioNTech pays $205M for FDA voucher to speed up 'late-stage oncology pipeline'
11.11.Aurobindo unit Eugia recalls antibiotic lot, citing glass particle concerns
10.11.ImmunityBio juggles phase 3 win and 20% stock crash en route to Anktiva front-line expansion
10.11.Summit sheds commercial leaders ahead of ivonescimab's FDA decision
10.11.J&J readies Caplyta for FDA label expansion after 2nd phase 3 win in bipolar mania
10.11.After court win, WuXi AppTec scores removal from US list of Chinese military companies
10.11.FDA orders new eye risk be listed on a dozen GLP-1s, including Novo's Ozempic, Lilly's Zepbound
10.11.Phillips Medisize strikes deal to expand UK inhalation production
10.11.Vertex lays off 78 Crinetics staffers amid $10B integration
10.11.Insulet, Marvel Comics smash diabetes stigma with new Omnipod-powered superhero
10.11.Bayer brings factor XIa to US stroke prevention with FDA nod for 1st-in-class asundexian
09.11.Veradermics wraps phase 3 program in men with 'better-than-expected' hair growth at 1 year
09.11.FDA opens safety probe into Novartis' Zolgensma over potential tumor risks
09.11.J&J's Icotyde pill drives biologic-like efficacy in psoriatic arthritis despite high-dose miss
09.11.Lilly looks to gird Foundayo label after late-stage win in sleep apnea
09.11.Moderna moves UK commercial digs to heart of London's 'knowledge quarter'
09.11.Agentic AI Is Rewriting The Pharma Marketing Playbook
09.11.Asking More of Science: How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care
06.11.Actor Jeremy Pope joins ViiV's 'PrEP Wisdom' campaign to educate on long-acting PrEP options